Smoking and oestrogen-replacement therapy as protective factors for Alzheimer's disease

Lancet

Volumn 349, Issue 9049, 1997, Pages 403-404

  Lerner, Alan ^a   Koss, Elisabeth ^b   Debanne, Sara ^b   Rowland, Douglas ^b   Smyth, Kathleen ^b   Friedland, Robert ^b  

^a St Luke's Hospital Cleveland   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN;

ALZHEIMER DISEASE; ARTICLE; CASE CONTROL STUDY; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DISEASE PREDISPOSITION; ESTROGEN THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SMOKING;

EID: 0031051509     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)80025-6     Document Type: Article

References (5)

1. Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol 1994; 140: 256-61.
2. Tang M-X, Jacobs D, Stern Y, et al. Effects of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996; 348: 429-32.
3. Barren-Connor E, Kritz-Silverstein D. Estrogen replacement therapy and cognitive function in older women. JAMA 1993; 269: 2637-41.
4. Luine V. Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats. Exp Neurol 1985; 89: 484-90.
5. Mayeux R, Ottman R, Maestre G, et al. Synergistic effects of traumatic head injury and apolipoprotein - ε4 in patients with Alzheimer's disease. Neurology 1995; 45: 555-57.